Lipoprotein(a) as a cardiovascular risk factor: current status

Apolipoprotein(a) Isoforms and the Risk of Vascular Disease

(2010) Sebhat Erqou et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia

(2010) Paul W. Ladenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk

(2010) M. John Chapman et al.   PHARMACOLOGY & THERAPEUTICS

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

(2009) Eric Bruckert et al.   ATHEROSCLEROSIS

Lipoprotein a: where are we now?

(2009) Konstantinos Tziomalos et al.   CURRENT OPINION IN CARDIOLOGY

Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere

(2009) Børge G Nordestgaard   CURRENT OPINION IN LIPIDOLOGY

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

(2009) Allen J. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective Data

(2008) Anna Bennet   ARCHIVES OF INTERNAL MEDICINE

Recommendations for the use of LDL apheresis

(2008) G.R. Thompson   ATHEROSCLEROSIS

Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice

(2008) Esther Merki et al.   CIRCULATION

Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events

(2008) Jacqueline Suk Danik et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation

(2008) N. T. FERIC et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

(2007) Pia R. Kamstrup et al.   CIRCULATION